Navigation Links
Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas
Date:5/22/2008

CAM)-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. The fourth clinical stage antibody is MT293 which is licensed to TRACON Pharmaceuticals, Inc. and is being developed in a phase 1 clinical trial for the treatment of patients with cancer. In addition, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, the risk that we or our collaborators will not obtain approval to market our product candidates, the risks associated with reliance on ou
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
2. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
3. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
4. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
5. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
6. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
7. Micromet Announces Changes in Management Team
8. Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration
9. Abbott Presents Long-Term Data From Extension Study Showing Adult Crohns Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission
10. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
11. Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at the Digestive Disease Week Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , Sept. 16, 2014  Denovo Biopharma, LLC, ... late-stage oncology drug, from Eli Lilly and Company ... manufacture and commercialize enzastaurin globally, including transfer of ... information. Lilly developed enzastaurin in ... and Phase 3 clinical trials for diffuse large ...
(Date:9/16/2014)... Wash. , Sept. 16, 2014 /PRNewswire/ ... a late stage development company engaged primarily ... medical isotopes for diagnostic and therapeutic applications, ... for technology related to its brachytherapy products.  ... arise from its license from Battelle, under ...
(Date:9/16/2014)... -- Russia,s pharmaceutical ... Pharma 2020 Strategy provides incentives for local producers to ... foreign markets. These trends, however, were affected by recent ... political and economic sanctions imposed on Russia ... Russia responded to the US ...
Breaking Medicine Technology:Denovo Biopharma Acquires Late-Stage Oncology Drug From lilly For Development As A Personalized Medicine 2Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 2Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 3Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 4Global Medicines for Russia 2
(Date:9/17/2014)... Irvington, NY (PRWEB) September 17, 2014 ... youth sports, concussion prevention is top of mind ... developed five facts to remember about concussions and ... Treatment, developed for kids, parents, coaches and teachers ... , "As a pediatric orthopedic ...
(Date:9/17/2014)... Lee Berman, a seasoned veteran of ... on The Balancing Act® airing on Lifetime Television®. Berman ... segment will premiere on September 19 and re-air on ... on Lifetime Television®' with show host Julie Moran. Berman ... over a decade and is the Director of Marketing ...
(Date:9/17/2014)... Freeslate, Inc. , the leading ... development, today announced that Baylor University acquired a ... to both support Baylor research interests and provide ... throughput system is expected to significantly accelerate innovation ... for small molecule organic chemistry. , The ...
(Date:9/17/2014)... Presence Technology, a multinational provider ... Suite 10.0, which incorporates significant enhancements to meet ... , The Contact Center Agents and Supervisors will ... get a better feel for the performance of ... and who requires additional coaching or mentoring to ...
(Date:9/16/2014)... BamboofloorChina.com, the popular online supplier of elegant bamboo items, ... bamboo floors to its product catalogue. Along with ... new items; the current discount is up to 27 ... season. Therefore, BamboofloorChina.com spares no energy to offer more ... items offered by BamboofloorChina.com are in stock and ready ...
Breaking Medicine News(10 mins):Health News:Video Helps Kids and Adults Talk About Concussion Recognition and Treatment 2Health News:Lee Berman Will Appear On The Balancing Act® airing on Lifetime Television® 2Health News:Baylor University Selects Freeslate Reaction Screening System to Support New High Throughput Screening Lab 2Health News:Presence Technology’s 10.0 Release Drives Contact Center Web Supervisor Effectiveness While Reducing Operation Costs and Delivering Enterprise Grade Scalability 2Health News:BamboofloorChina.com Announces Its Promotion For Strand Woven Bamboo Floors 2
... VIEJO, Calif., Sept. 19 Clarient, Inc.,(Nasdaq: CLRT ... and the pharmaceutical industry, today announced,that it is scheduled ... Life Sciences Conference at 4:30 p.m. EDT on Wednesday, ... Grand Hyatt in New York City,September 24-27. A ...
... /Xinhua-PRNewswire-FirstCall/ -- To help buyers,identify suppliers offering ... GSOL ) and Bureau Veritas, one ... have launched the B2B industry,s,most comprehensive supplier ... ) Co-developed by the two companies, ...
... volunteers representing the Women,s Dermatologic Society (WDS) will, help ... free skin cancer screenings and sun safety ... PLANO, Texas, Sept. 18 Even though higher altitudes,mean ... balloon,enthusiasts enjoying the upcoming Plano Hot Air Balloon Festival ...
... following statement today on proposed legislation by Senators,Kent Conrad ... to create a,task force to reform Social Security and ... the most successful safety,nets in our nation and any ... be done by the committees of jurisdiction in Congress; ...
... and other tissue in the laboratory in conditions similar to ... The technology, developed and patented by scientists at Durham University ... which allows cells to be grown in a more realistic ... a Petri dish. , Evidence gathered by the research ...
... ELMHURST, Ill., Sept. 18 Secure Services Corp. ... Parke has joined,them as the Director of Business ... northwest suburbs for 22 years. He was an,acknowledged ... of the National Conference of Insurance Legislators (NCOIL). ...
Cached Medicine News:Health News:Clarient to Present at the UBS 2007 Global Life Sciences Conference 2Health News:Supplier Assessments to Help Buyers Identify Reliable China Exporters 2Health News:Supplier Assessments to Help Buyers Identify Reliable China Exporters 3Health News:Supplier Assessments to Help Buyers Identify Reliable China Exporters 4Health News:Sun Safety Outreach to Families Takes Flight at the Plano Hot Air Balloon Festival 2Health News:Sun Safety Outreach to Families Takes Flight at the Plano Hot Air Balloon Festival 3Health News:Cell growth technology promises more successful drug development 2Health News:Cell growth technology promises more successful drug development 3Health News:Former State Representative Terry Parke Joins Secure Services Corp. 2
... thin collagen coated highly compliant ... thin wall construction offers optimal ... Hemacarotid UltraThin Patch provides superb ... and healing, without suture hole ...
The VasoSeal Low Profile device is designed for smaller sheath angiography procedures. VasoSeal Low Profile. Seal your arterial punctures with confidence....
D-Stat Radial is a dry version of the D-Stat together with a compression band, and is designed for the control of surface bleeding from vascular access sites, including the sites on the radial artery...
... engineered to close arteriotomies with ease ... with a simple trigger actvated mechanism, ... deliver sheath gently locks onto the ... the site before, during, and after ...
Medicine Products: